PARP1 and cancer: Although several therapies are approved as cancer treatments, from conventional to targeted therapies, including VEGF inhibitors, immunotherapies, and PARP inhibitors, appearance of chemoresistance hinders the therapeutic benefits, highlighting the need to develop biomarker-based therapies to address these challenges [2,3,4,5,6].